Skip to content
PeptideFactSheets
FDA approved for specific usesStrong human evidence for approved uses

Plain-English fact sheet

Pramlintide

Also known as Symlin, pramlintide acetate

Diabetes and glucose controlWeight managementMetabolic health

Pramlintide replaces some effects of the pancreatic hormone amylin. Its approved diabetes role is narrow, while stand-alone obesity and consumer weight-loss claims are not approved.

Quick answer

Pramlintide is FDA approved as Symlin for certain people with type 1 or type 2 diabetes who use mealtime insulin and have not reached glycemic goals. It is not FDA approved as a stand-alone obesity medicine.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

What is Pramlintide?

Pramlintide is a manufactured analog of amylin, a peptide hormone normally released with insulin after eating.

Amylin signaling affects stomach emptying, glucagon release, satiety, and blood glucose, which also made the pathway important in obesity-drug research.

Why are people interested in it?

It is the established clinical proof that amylin biology can be used therapeutically.

Weight changes in diabetes and older obesity trials helped motivate longer-acting amylin analogs such as cagrilintide, but the molecules and evidence are not interchangeable.

Current regulatory status

FDA approved for specific uses

Symlin is FDA approved as an adjunct for selected adults with type 1 or type 2 diabetes who use mealtime insulin and have not achieved desired glucose control despite appropriate insulin management.

What is it approved for?

  • Adjunctive treatment in the insulin-treated diabetes populations specified by the Symlin label

FDA approval path

FDA approved

FDA approved as an adjunct diabetes medicine

Pramlintide is approved under the Symlin label for specified insulin-treated diabetes populations. Its investigational weight history does not create a weight-loss approval.

Step 7 of 7

  1. DiscoveryBasic research
  2. PreclinicalLab and animal work
  3. Phase 1Initial human testing
  4. Phase 2Condition-focused trials
  5. Phase 3Confirmatory trials
  6. FDA reviewApplication review
  7. ApprovedLabel-specific use

Timeline source basis

FDA prescribing information: SymlinOne-year randomized pramlintide diabetes trialRandomized pramlintide obesity study

What is it being studied for?

Glucose control with mealtime insulin
Satiety and food intake
Obesity and weight outcomes

Investigational areas

  • Obesity treatment outside the approved diabetes context
  • Amylin-based combination medicines

Evidence snapshot

Strong human evidence for approved uses

Randomized trials support the scoped diabetes indication. Obesity research without insulin-treated diabetes is older and does not create a current stand-alone weight-management approval.

Potential benefits being researched

  • Controlled diabetes trials showed improved glycemic outcomes when pramlintide was added in the labeled setting.
  • Older obesity trials found weight-loss signals, but pramlintide did not become a stand-alone FDA-approved obesity medicine.

Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.

Known or possible risks

  • The label carries a boxed warning for severe hypoglycemia when used with mealtime insulin, especially in type 1 diabetes.
  • Nausea and other gastrointestinal effects are common.
  • Its approved use requires clinical management that cannot be generalized to consumer weight-loss use.

What we still do not know

  • Whether pramlintide has a useful modern obesity role compared with other agents
  • Long-term outcomes for unapproved weight-management use
  • How benefits and harms compare with longer-acting amylin analogs
  • Which combination strategies, if any, will prove clinically superior

Plain-English takeaway

Pramlintide validates amylin as a therapeutic pathway, but its real approval is a narrow diabetes adjunct—not general weight loss.

Research and reference links

Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.

  1. 1
    fdaFDA prescribing information: Symlin

    Approved population, boxed warning, adverse reactions, and clinical evidence.

  2. 2
    pubmedOne-year randomized pramlintide diabetes trial

    Controlled evidence for glycemic and weight outcomes in insulin-treated type 2 diabetes.

  3. 3
    pubmedRandomized pramlintide obesity study

    Older exploratory obesity study that does not establish an approved stand-alone use.